Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Eftimov

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Allergy|March 5, 2024
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccinationAnika M Valk, Jim B D Keijser, Koos P J van Dam, et al.
Journal of Autoimmunity|February 22, 2024
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8<sup>+</sup> T cell responsesJet van den Dijssel, Mariël C Duurland, Veronique Al Konijn, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 28, 2024
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccinationNiels J M Verstegen, Ruth R Hagen, Christine Kreher, et al.
RMD Open|October 7, 2024
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMIDLaura Y L Kummer, Laura Fernández Blanco, Christine Kreher, et al.
The Journal of Dermatology|February 14, 2025
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyNicoline F van Buchem-Post, Wouter Ouwerkerk, Eileen W Stalman, et al.
The Lancet. Microbe|December 21, 2024
Immune responses to SARS-CoV-2 in sub-Saharan Africa and western Europe: a retrospective, population-based, cross-sectional studyMoustapha Mbow, Dennis Hoving, Marouba Cisse, et al.
NPJ Digital Medicine|June 4, 2026
ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world casesAlberto De Lorenzo, Giulia Sofia Moretti, Alessandro Bertini, et al.
Annals of Neurology|November 27, 2024
Long-Term Follow Up in Anti-Contactin-1 Autoimmune NodopathyMarta Caballero-Ávila, Lorena Martín-Aguilar, Elba Pascual-Goñi, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
The Lancet. Neurology|March 20, 2021
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trialChrista Walgaard, Bart C Jacobs, Hester F Lingsma, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Allergy|March 5, 2024
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccinationAnika M Valk, Jim B D Keijser, Koos P J van Dam, et al.
Journal of Autoimmunity|February 22, 2024
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8<sup>+</sup> T cell responsesJet van den Dijssel, Mariël C Duurland, Veronique Al Konijn, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 28, 2024
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccinationNiels J M Verstegen, Ruth R Hagen, Christine Kreher, et al.
RMD Open|October 7, 2024
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMIDLaura Y L Kummer, Laura Fernández Blanco, Christine Kreher, et al.
The Journal of Dermatology|February 14, 2025
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyNicoline F van Buchem-Post, Wouter Ouwerkerk, Eileen W Stalman, et al.
The Lancet. Microbe|December 21, 2024
Immune responses to SARS-CoV-2 in sub-Saharan Africa and western Europe: a retrospective, population-based, cross-sectional studyMoustapha Mbow, Dennis Hoving, Marouba Cisse, et al.
NPJ Digital Medicine|June 4, 2026
ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world casesAlberto De Lorenzo, Giulia Sofia Moretti, Alessandro Bertini, et al.
Annals of Neurology|November 27, 2024
Long-Term Follow Up in Anti-Contactin-1 Autoimmune NodopathyMarta Caballero-Ávila, Lorena Martín-Aguilar, Elba Pascual-Goñi, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
The Lancet. Neurology|March 20, 2021
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trialChrista Walgaard, Bart C Jacobs, Hester F Lingsma, et al.
Pageof 10